Neuropathix Revenue Growth Rates (TYGS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Neuropathix Inc.  (TYGS)
 

TYGS's Revenue Growth by Quarter and Year

Neuropathix's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

TYGS Revenue (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 0.21
FY 0.21

TYGSs Annual Revenue
Neuropathix's Revenue in the fiscal year 2021 $ 0.18 millions
Neuropathix's Revenue in the fiscal year 2020 $ 0.00 millions
Neuropathix's Revenue in the fiscal year 2019 $ 0.13 millions
Neuropathix's Revenue in the fiscal year 2018 $ 0.17 millions
Neuropathix's Revenue in the fiscal year 2017 $ 0.00 millions




TYGS Revenue first quarter 2022 Y/Y Growth Comment
Neuropathix Inc. achieved in the first quarter 2022, above Company average Revenue surge of 593.27% year on year, to $ 0.21 millions.

Looking into first quarter 2022 results within Major Pharmaceutical Preparations industry 2 other companies have achieved higher Revenue growth. While Neuropathix Inc.' s Revenue doubling of 593.27% ranks overall at the positon no. 88 in the first quarter 2022.


TYGS Revenue ( Y/Y Growth %) 2022
 2021 2020 2019
4th Quarter December - - - -
3rd Quarter September - - - -50 %
2nd Quarter June - - - 25 %
1st Quarter March 593.27 % - - 66.67 %
FY   - - - -

Financial Statements
Neuropathix's first quarter 2022 Revenue $ 0.21 millions TYGS's Income Statement
Neuropathix's first quarter 2021 Revenue $ 0.03 millions Quarterly TYGS's Income Statement


TYGS Revenue (Quarter on Quarter Growth %)

 2022
 2021 2020 2019
4th Quarter December - 200 % - -
3rd Quarter September - - - -60 %
2nd Quarter June - - - 0 %
1st Quarter March 73.32 % - - -28.57 %
FY (Year on Year)   - - - -


Back to TYGS Growth rate Comparisons >> Back to TYGS Growth rate Comparisons >>


Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #6
Overall #88

Revenue Y/Y Growth Statistics
High Average Low
549.94 % 69.6 % -100 %
(Mar 31 2022)   (Dec 31 2020)
Revenue first quarter 2022 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #3
Healthcare Sector #6
Overall #88
Revenue Y/Y Growth Statistics
High Average Low
549.94 % 69.6 % -100 %
(Mar 31 2022)   (Dec 31 2020)

Revenue by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Neuropathix's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
256.39 % 50.67 % -100 %
(Dec 31 2018)  


TYGS's I. Quarter Q/Q Revenue Comment
Neuropathix Inc. achieved in the I. Quarter 2022 above company average sequential Revenue jump of 73.32%, to $ 0.21 millions, from $0.12 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Neuropathix's Revenue growth quarter on quarter, overall rank is 191.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #32
Overall #191
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #15
Healthcare Sector #32
Overall #191
Revenue Q/Q Growth Statistics
High Average Low
256.39 % 50.67 % -100 %
(Dec 31 2018)  


TYGS's I. Quarter Q/Q Revenue Comment
Neuropathix Inc. achieved in the I. Quarter 2022 above company average sequential Revenue jump of 73.32%, to $ 0.21 millions, from $0.12 millions in the fourth quarter.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Revenue quarter on quarter growth. While Neuropathix's Revenue growth quarter on quarter, overall rank is 191.


Neuropathix's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2022)		 12 Months Ending
(Dec 31 2021)		 12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)
Cumulative Revenue 12 Months Ending $ 0.00 $ 0.00 $ 0.00 $ 0.00 $ 0.00
Y / Y Revenue Growth (TTM) - - - - -
Year on Year Revenue Growth Overall Ranking # # # # #
Seqeuential Revenue Change (TTM) - - - - -
Seq. Revenue Growth (TTM) Overall Ranking # # # # #


Cumulative Revenue growth Comment
In the Mar 31 2022 period, Neuropathix's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Neuropathix Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Revenue growth Comment
In the Mar 31 2022 period, Neuropathix's cumulative trailing twelve month Revenue remained unchanged compare to the same period a year ago.

Neuropathix Inc. achieved highest trailing twelve month year on year Revenue growth. While overall Revenue growth ranking, remained unchanged compare to the previous quarter at no. .


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #
Healthcare Sector #
Overall #

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
TYGS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Mar 31 2022 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2022
Ethema Health Corporation 1,027.09%$ 1,027.086 millions
Aveo Pharmaceuticals Inc 989.58%$ 989.583 millions
Petvivo Holdings Inc 951.37%$ 951.374 millions
Clearside Biomedical Inc 920.59%$ 920.588 millions
Guardion Health Sciences Inc 798.62%$ 798.621 millions
Histogen Inc 771.23%$ 771.230 millions
Gain Therapeutics inc754.17%$ 754.166 millions
Ascendis Pharma A752.25%$ 752.248 millions
Xoma Royalty Corporation728.53%$ 728.533 millions
Marinus Pharmaceuticals Inc 685.49%$ 685.493 millions
Chinook Therapeutics Inc 668.38%$ 668.376 millions
Inotiv Inc 648.30%$ 648.296 millions
Pear Therapeutics Inc 631.12%$ 631.117 millions
Biohaven Ltd 627.59%$ 627.591 millions
Prothena Corporation Public Limited Company620.63%$ 620.625 millions
Scholar Rock Holding Corp605.03%$ 605.034 millions
Neuropathix Inc.549.94%$ 549.938 millions
Alector Inc 495.47%$ 495.474 millions
Arbutus Biopharma Corp495.41%$ 495.409 millions
Intelligent Bio Solutions Inc 461.22%$ 461.224 millions
Fresh Tracks Therapeutics Inc 441.18%$ 441.176 millions
Lftd Partners Inc 439.44%$ 439.440 millions
Denali Therapeutics Inc 431.88%$ 431.882 millions
Prometheus Biosciences Inc 415.66%$ 415.658 millions
Skinvisible Inc 397.72%$ 397.718 millions
Caremax Inc 390.44%$ 390.436 millions
Arvinas Inc 378.39%$ 378.394 millions
Tenon Medical Inc 373.33%$ 373.333 millions
Evoke Pharma Inc 362.70%$ 362.702 millions
Arrowhead Pharmaceuticals Inc 362.66%$ 362.665 millions


About Neuropathix Revenue Growth Rates (TYGS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Neuropathix Inc (CIK 1615999).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001607062-22-000388
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Neuropathix Inc ’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.